FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPRO	VAL					
OMB Number:	3235-0287					
Estimated average burde	en					
hours per response:	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					(or Sec	tion 30(h)	of the	e Investmen	t Cor	npany Act	of 1940)							
Name and Address of Reporting Person* COURY ROBERT J							r Name an s Inc		ker or Tradi	ng S	ymbol	(Che	elationship o eck all applica	able)	g Perso	on(s) to Issuer				
(Last) (First) (Middle) 1000 MYLAN BOULEVARD						3. Date of Earliest Transaction (Month/Day/Year) 11/16/2020									below)	give title Other (spe- below) Executive Chairman		pecify		
(Street) CANONSBURG PA 15317						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(City) (State) (Zip)													Form filed by More than One Reporting Person							
		Та	ble I - No	n-Der	rivati	ve Se	ecurities	s Ac	cquired,	Dis	posed c	of, or	Bene	ficially	y Owned					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						Execution Date		Code (Instr						5. Amour Securitie Beneficia Owned F Reported	s illy ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	nt (A) or (D)		Price	Transacti (Instr. 3 a	on(s) nd 4)				
Common	Stock(1)			11/	16/20	/2020			A		1,383,5	587 A		(2)	1,38	3,587		D		
			Table II -						լuired, D s, option						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	ate,	4. Transa Code (8)		Derivative E		6. Date Exercisable an Expiration Date (Month/Day/Year)			7. Title and Amof Securities Underlying Derivative Secu (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio	Ow s For lly Dire or l	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisabl		expiration Date	Title	or N	nount ımber Shares		(Instr. 4)	ion(s)			
Employee Stock Option - Right to Buy ⁽³⁾	\$22.66	11/16/2020			A		4,413		(4)	0	3/02/2021	Comm		4,413	(3)	4,413	3	D		
Employee Stock Option - Right to Buy ⁽³⁾	\$23.44	11/16/2020			A		4,266		(5)	0	2/22/2022	Comm		4,266	(3)	4,260	6	D		
Employee Stock Option - Right to Buy ⁽³⁾	\$30.9	11/16/2020			A		3,236		(6)	0	3/06/2023	Comm		3,236	(3)	3,236	6	D		
Employee Stock Option - Right to Buy ⁽³⁾	\$55.84	11/16/2020			A		58,952		(7)	0	3/05/2024	Comm		8,952	(3)	58,95	52	D		
Employee Stock Option - Right to Buy ⁽³⁾	\$50.66	11/16/2020			A		63,235		(8)	1	1/17/2025	Comm		3,235	(3)	63,23	5	D		
Employee Stock Option - Right to Buy ⁽³⁾	\$46.27	11/16/2020			A		82,776		(9)	0	2/17/2026	Comm		2,776	(3)	82,77	16	D		
Restricted Stock	\$0.00	11/16/2020			A		250,000		(11)	T	(11)	Comm	on 2	50,000	(10)	250,00	00	D		

Explanation of Responses:

- 1. On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).
- 2. Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was \$15.85 per share
- 3. Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.
- 4. These options vested on March 2, 2014.
- 5. These options vested on February 22, 2015.
- 6. These options vested on March 6, 2016.
- 7. These options vested on March 5, 2017.
- 8. These options vested on March 4, 2018.
- 9. These options vested on February 17, 2019.
- 10. Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

11. Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on June 24, 2021.

Remarks:

/s/ Kevin Macikowski, by power of attorney

** Signature of Reporting Person D

11/18/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.